{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:47Z","timestamp":1786119467653,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1097\/coc.0b013e31819fdf5e","type":"journal-article","created":{"date-parts":[[2010,1,30]],"date-time":"2010-01-30T02:27:18Z","timestamp":1264818438000},"page":"83-88","source":"Crossref","is-referenced-by-count":23,"title":["Phase II Study of Plitidepsin 3-Hour Infusion Every 2 Weeks in Patients With Unresectable Advanced Medullary Thyroid Carcinoma"],"prefix":"10.1097","volume":"33","author":[{"given":"Eric","family":"Baudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean P.","family":"Droz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan T.","family":"van Oosterom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cullell-Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210128","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0046-8177(88)80262-4","article-title":"C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors.","volume":"19","author":"Albores-Saavedra","year":"1988","journal-title":"Hum Pathol"},{"key":"R2-17-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/eje.0.1430015","article-title":"Innovative strategies for the treatment of thyroid cancer.","volume":"143","author":"Schmutzler","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"R3-17-20210128","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11864-005-0037-7","article-title":"Medullary thyroid cancer: medical management and follow-up.","volume":"6","author":"Traugott","year":"2005","journal-title":"Curr Treat Options Oncol"},{"key":"R4-17-20210128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0030-6665(20)31272-X","article-title":"Radioiodine and radiotherapy in the management of thyroid cancers.","volume":"23","author":"Simpson","year":"1990","journal-title":"Otolaryngol Clin North Am"},{"key":"R5-17-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0889-8529(05)70316-9","article-title":"External radiation therapy in the treatment of thyroid malignancy.","volume":"25","author":"Brierley","year":"1996","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R6-17-20210128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<132::AID-CNCR19>3.0.CO;2-5","article-title":"Long-term follow-up of patients with medullary carcinoma of the thyroid.","volume":"79","author":"Bergholm","year":"1997","journal-title":"Cancer"},{"key":"R7-17-20210128","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","article-title":"Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.","volume":"88","author":"Kebebew","year":"2000","journal-title":"Cancer"},{"key":"R8-17-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1074\/jbc.M201010200","article-title":"Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK.","volume":"278","author":"Cuadrado","year":"2003","journal-title":"J Biol Chem"},{"key":"R9-17-20210128","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdi311","article-title":"VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia.","volume":"16","author":"Biscardi","year":"2005","journal-title":"Ann Oncol"},{"key":"R10-17-20210128","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.cdd.4401898","article-title":"Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase down regulation.","volume":"13","author":"Gonzalez-Santiago","year":"2006","journal-title":"Cell Death Differ"},{"key":"R11-17-20210128","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/jpet.107.132662","article-title":"Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1\/c-Jun NH2-terminal kinase activation in human melanoma cells.","volume":"324","author":"Munoz-Alonso","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R12-17-20210128","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1210\/er.2002-0008","article-title":"Angiogenesis in endocrine tumors.","volume":"24","author":"Turner","year":"2003","journal-title":"Endocr Rev"},{"key":"R13-17-20210128","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/bjc.1998.570","article-title":"In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and hematopoietic precursor cells.","volume":"78","author":"Depenbrock","year":"1998","journal-title":"Br J Cancer"},{"key":"R14-17-20210128","first-page":"333","article-title":"Effect of dehydrodidemnin B on human colon carcinoma cell lines.","volume":"17","author":"Lobo","year":"1997","journal-title":"Anticancer Res"},{"key":"R15-17-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0304-3835(96)04151-1","article-title":"Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates.","volume":"102","author":"Urdiales","year":"1996","journal-title":"Cancer Lett"},{"key":"R16-17-20210128","doi-asserted-by":"crossref","first-page":"7780","DOI":"10.1200\/JCO.2005.09.357","article-title":"Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.","volume":"23","author":"Faivre","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-17-20210128","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/annonc\/mdl165","article-title":"Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.","volume":"17","author":"Maroun","year":"2006","journal-title":"Ann Oncol"},{"key":"R20-17-20210128","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1078-0432.CCR-07-1652","article-title":"Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.","volume":"14","author":"Izquierdo","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R21-17-20210128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00001813-200404000-00003","article-title":"Progress in the clinical development of new marine-derived anticancer compounds.","volume":"15","author":"Jimeno","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R22-17-20210128","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.1996.14.6.1957","article-title":"Update of recommendations for the use of hematopoietic colony-stimulating factor: evidence-based clinical practice guidelines.","volume":"14","year":"1996","journal-title":"J Clin Oncol"},{"key":"R23-17-20210128","article-title":"The Thyroid: A Fundamental and Clinical Text. 7th ed.","author":"Ball","year":"1996"},{"key":"R24-17-20210128","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00000658-199911000-00013","article-title":"Surgical strategy for the treatment of medullary thyroid carcinoma.","volume":"230","author":"Fleming","year":"1999","journal-title":"Ann Surg"},{"key":"R25-17-20210128","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"R26-17-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","article-title":"The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.","volume":"13","author":"Gehan","year":"1961","journal-title":"J Chronic Dis"},{"key":"R27-17-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/bjc.1995.73","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).","volume":"71","author":"Schlumberger","year":"1995","journal-title":"Br J Cancer"},{"key":"R28-17-20210128","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1054\/bjoc.2000.1314","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC).","volume":"83","author":"Nocera","year":"2000","journal-title":"Br J Cancer"},{"key":"R29-17-20210128","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<372::AID-CNCR23>3.0.CO;2-P","article-title":"5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.","volume":"83","author":"Bajetta","year":"1998","journal-title":"Cancer"},{"key":"R30-17-20210128","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1200\/jco.2006.24.18_suppl.5533","article-title":"A phase II trial of ZD6474 in patients with hereditary metastatic medullaty thyroid cancer.","volume":"24","author":"Wells","year":"2006","journal-title":"J Clin Oncol"},{"key":"R31-17-20210128","first-page":"579A","article-title":"A phase 2 study of Axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer.","volume":"17","author":"Kim","year":"2006","journal-title":"Ann Oncol"},{"key":"R32-17-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2008.06.017","article-title":"Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.","volume":"64","author":"Eisen","year":"2009","journal-title":"Lung Cancer"},{"key":"R33-17-20210128","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.lungcan.2007.10.019","article-title":"Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non\u2013small-cell lung cancer.","volume":"60","author":"Peschel","year":"2008","journal-title":"Lung Cancer"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0b013e31819fdf5e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:18:42Z","timestamp":1786040322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201002000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31819fdf5e","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}